openPR Logo
Press release

Conagen Wins SynBioBeta Award for Non-GMO HMO and Human Lactoferrin

09-29-2020 10:15 AM CET | Health & Medicine

Press release from: Conagen

Conagen leads in nutrition

Conagen leads in nutrition

Bedford, Mass. (Sept. 29 2020) --- SynBioBeta’s (SBB) Synthetic Biology Global Conference awarded Conagen the “Best Product of the Year” for its human lactoferrin and non-GMO human milk oligosaccharide (HMO.)

Human lactoferrin is a critical iron-binding compound for immunity and iron nutrition. HMOs are important nutritional compounds only found in human milk. The most abundant HMO in human milk is 2’-fucosyllactose (2’FL), and it is responsible for promoting good gut bacteria, strengthening the gut barrier function, and suppressing pathogens.

“Conagen is honored to accept this award from SynBioBeta for our human lactoferrin and non-GMO HMO infant formula ingredients, but we do not intend to stop there. We are dedicated to continuously improving infant health and nutrition by expanding our portfolio with many more innovative infant formula ingredients,” said VP of Innovation, Dr. Casey Lippmeier.

In addition to their human lactoferrin and non-GMO HMO and products, Conagen is the first company to commercialize an odorless and tasteless butyrate releaser, otherwise known as FBA. FBA delivers butyrate, a short-chain fatty acid that helps infants develop gut and immune systems for mitigating a number of pathologies, including common food allergies to cow’s milk (1). It is an important health postbiotic and probiotic molecule for building gut health and immunity.

While Conagen’s FBA has been licensed in the infant formula space, there are partnership opportunities still available in applications spanning food and beverage, medical nutrition, dietary supplements, and pharmaceuticals.

“Today we are announcing our third offering for infant formula fortification, a compound which delivers butyrate to the infant gut in a way which safely conveys its important, well-characterized post-biotic effects, while retaining the accepted flavor of formula for babies’ palates,” said Lippmeier.

References:
Canani, Roberto Berni, et al. "Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants." The ISME journal 10.3 (2016): 742-750.

###

Conagen
15 DeAngelo
Bedford, MA, 01730
USA
Contact: Ana Arakelian
ana.arakelian@conagen.com

About Conagen
Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop high-quality sustainable nature-based products through systems of manufacturing on a molecular level and fermentation basis. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Conagen Wins SynBioBeta Award for Non-GMO HMO and Human Lactoferrin here

News-ID: 2145405 • Views:

More Releases for HMO

HMO Market is Projected to Reach $556 million by 2027
The global HMO market is estimated to be valued at USD 199 million in 2022. It is projected to reach USD 556 million by 2027, recording a CAGR of 22.7% during the forecast period. The global HMO market has been influenced by some of the macroeconomic and microeconomic factors witnessed in some key countries. This would prove strong enough to drive the market significantly in terms of value
Live Launch of JumboTiger (Coliving, HMO and Property Management Software)
JumboTiger is a full-stack real-time conversational property management software. It helps landlords/ owners, property managers, coliving & HMO operators to manage their rental portfolio. Lunch on - 16th Feb, 2021, 04:00PM GMT Register link for launch - https://zoom.us/webinar/register/WN_4B8oQpelR-KXFn17HdIyog What made you start your startup and what problem does it solve? We were running a successful bootstrapped coliving startup called [simplyguest.com] since 2015. We were growing at 10-15% m-o-m and had built a pretty successful business.
Human Milk Oligosaccharides (HMO) Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Human Milk Oligosaccharides (HMO) Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-human-milk-oligosaccharides-hmo-market-research-report-2017-1541215 In this report, the global Human Milk Oligosaccharides (HMO) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented
Global Human Milk Oligosaccharides (HMO) Market Research Report 2016
This report studies Human Milk Oligosaccharides (HMO) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Beghin Meiji (France) Beneo-Orafti SA (Belgium) Cargill, Inc. (US) Cosucra Groupe Warcoing SA (Belgium) Ingredion Incorporated (US) Royal Cosun (The Netherlands) Sensus (The Netherlands) Yakult Pharmaceutical Industry Co., Ltd. (Japan) Major Manufacturers of Prebiotic Food Products Abbott Nutrition (US) Clasado BioSciences
Global Human Milk Oligosaccharides (HMO) Market- Inbiose, Elicityl SA, ZuChem, G …
Global Market Study Evaluate on Human Milk Oligosaccharides (HMO) Industry by Type, Manufacturers, Application, Type, and Regions, Forecast up to 2022 The scope of the global Human Milk Oligosaccharides (HMO) market report is: Global Human Milk Oligosaccharides (HMO) MarketThis report offers a comprehensive evaluation of the Human Milk Oligosaccharides (HMO) market. It does so by in-depth qualitative insights, historical Human Milk Oligosaccharides (HMO) market data, and verifiable projections about global Human Milk
Human Milk Oligosaccharides (HMO) Market - Global Industry Analysis 2024
Human Milk Oligosaccharides (HMO) is a complex bioactive sugar molecule present in human milk. It functions as growth substrates for particular beneficial bacteria. Due to being structurally complex and diverse, extracting or synthesizing them for use in the formula is challenging. As human milk oligosaccharides (HMO) is beneficial for microbiome and immunity, therefore, many new techniques are getting researched and developed by the key player which include extracting HMO from